Abstract
E067 Bimekizumab maintained efficacy responses through 52 weeks in biologic disease-modifying antirheumatic drugnaïve patients with psoriatic arthritis who were responders at week 16: results from BE OPTIMAL, a phase 3, activereference study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have